Amedeo Smart

Free Medical Literature Service

 

Amedeo

Dyslipidemia
  Free Subscription

Articles published in
Curr Opin Lipidol
    April 2024
  1. RASMUSSEN KL, Frikke-Schmidt R
    The current state of apolipoprotein E in dyslipidemia.
    Curr Opin Lipidol. 2024;35:78-84.
    >> Share

  2. WEN Y, Chen YQ, Konrad RJ
    Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism.
    Curr Opin Lipidol. 2024;35:58-65.
    >> Share

    February 2024
  3. PAPONJA K, Pecin I, Reiner Z, Banach M, et al
    Bempedoic acid: new evidence and recommendations on use.
    Curr Opin Lipidol. 2024;35:41-50.
    >> Share

  4. ZHANG Y, de Ferranti SD, Moran AE
    Genetic testing for familial hypercholesterolemia.
    Curr Opin Lipidol. 2024 Feb 1. doi: 10.1097/MOL.0000000000000925.
    >> Share

    December 2023
  5. PERERA SD, Hegele RA
    Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
    Curr Opin Lipidol. 2023 Dec 21. doi: 10.1097/MOL.0000000000000916.
    >> Share

  6. ROMERO-JIMENEZ MJ, Mansilla-Rodriguez ME, Gutierrez-Cortizo EN
    Predictors of cardiovascular risk in familial hypercholesterolemia.
    Curr Opin Lipidol. 2023;34:272-277.
    >> Share

  7. GILLARD BK, Rosales C, Gotto AM Jr, Pownall HJ, et al
    The pathophysiology of excess plasma-free cholesterol.
    Curr Opin Lipidol. 2023;34:278-286.
    >> Share

  8. KARALIS DG
    Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:252-258.
    >> Share

    November 2023
  9. ROY G, Drouin-Chartier JP
    Cardiovascular disease prevention in heterozygous familial hypercholesterolemia: how important is a healthy diet in the era of long-lasting cholesterol-lowering drug therapies?
    Curr Opin Lipidol. 2023 Nov 2. doi: 10.1097/MOL.0000000000000908.
    >> Share

    October 2023
  10. CHATTOPADHYAY A, Reddy ST, Fogelman AM
    The multiple roles of lysophosphatidic acid in vascular disease and atherosclerosis.
    Curr Opin Lipidol. 2023;34:196-200.
    >> Share

    August 2023
  11. CHOUDHARI P, Patni N
    Updates in the management of pediatric dyslipidemia.
    Curr Opin Lipidol. 2023;34:156-161.
    >> Share

    June 2023
  12. GANDA OP
    Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:105-113.
    >> Share

  13. WADSTROM BN, Pedersen KM, Wulff AB, Nordestgaard BG, et al
    Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:96-104.
    >> Share

    April 2023
  14. CLARKE SL
    Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?
    Curr Opin Lipidol. 2023;34:52-58.
    >> Share

  15. HEGELE RA
    DNA testing in dyslipidemia: attitudes and complexities.
    Curr Opin Lipidol. 2023;34:33-34.
    >> Share

    March 2023
  16. VUORIO A, Raal F, Kovanen PT
    Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19.
    Curr Opin Lipidol. 2023 Mar 10. doi: 10.1097/MOL.0000000000000876.
    >> Share

    February 2023
  17. HANG SMT, Hegele RA, Berberich AJ
    Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia.
    Curr Opin Lipidol. 2023 Feb 2. doi: 10.1097/MOL.0000000000000866.
    >> Share

    January 2023
  18. REIJMAN MD, Defesche JC, Wiegman A
    Genotype-phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2023 Jan 18. doi: 10.1097/MOL.0000000000000863.
    >> Share

    December 2022
  19. DRON JS
    The clinical utility of polygenic risk scores for combined hyperlipidemia.
    Curr Opin Lipidol. 2022 Dec 28. doi: 10.1097/MOL.0000000000000865.
    >> Share

  20. WEI T, Cho L
    Recent lipoprotein(a) trials.
    Curr Opin Lipidol. 2022;33:301-308.
    >> Share

  21. MENDOZA MF, Lavie CJ
    Clinical associations between exercise and lipoproteins.
    Curr Opin Lipidol. 2022;33:364-373.
    >> Share

  22. TRAMONTANO D, Bini S, D'Erasmo L, Arca M, et al
    Recent Apolipoprotein CIII trials.
    Curr Opin Lipidol. 2022;33:309-318.
    >> Share

    October 2022
  23. TROMP TR, Cuchel M
    New algorithms for treating homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2022 Oct 5. pii: 00041433-990000000-00014.
    >> Share

  24. SCIPIONE CA, Cybulsky MI
    Early atherogenesis: new insights from new approaches.
    Curr Opin Lipidol. 2022;33:271-276.
    >> Share

    August 2022
  25. MARTINS J, Rossouw HM, Pillay TS
    How should low-density lipoprotein cholesterol be calculated in 2022?
    Curr Opin Lipidol. 2022;33:237-256.
    >> Share

    July 2022
  26. LEREN TP, Bogsrud MP
    Cascade screening for familial hypercholesterolemia should be organized at a national level.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00004.
    >> Share

  27. DURRINGTON PN, Bashir B, Bhatnagar D, Soran H, et al
    Lipoprotein (a) in familial hypercholesterolaemia.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00005.
    >> Share

  28. PAQUETTE M, Bernard S, Baass A
    Diagnosis of remnant hyperlipidaemia.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00002.
    >> Share

    June 2022
  29. THEROND P, Chapman MJ
    Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment.
    Curr Opin Lipidol. 2022;33:199-207.
    >> Share

    April 2022
  30. WHITTAKER MN, Musunuru K
    Therapeutic application of genome editing in dyslipidemia.
    Curr Opin Lipidol. 2022;33:133-138.
    >> Share

    February 2022
  31. SACKS FM, Andraski AB
    Dietary fat and carbohydrate affect the metabolism of protein-based high-density lipoprotein subspecies.
    Curr Opin Lipidol. 2022;33:1-15.
    >> Share

    December 2021
  32. ANTONIAZI L, Arroyo-Olivares R, Mata P, Santos RD, et al
    Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Dec 13. pii: 00041433-900000000-99240.
    >> Share

  33. MEDEIROS AM, Bourbon M
    Polygenic contribution for familial hypercholesterolemia (FH).
    Curr Opin Lipidol. 2021;32:392-395.
    >> Share

  34. CHAN DC, Ying Q, Watts GF
    Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies.
    Curr Opin Lipidol. 2021;32:378-385.
    >> Share

  35. MATA P, Alonso R, Perez de Isla L, Badimon L, et al
    Dyslipidemia and aortic valve disease.
    Curr Opin Lipidol. 2021;32:349-354.
    >> Share

  36. KERSTEN S
    ANGPTL3 as therapeutic target.
    Curr Opin Lipidol. 2021;32:335-341.
    >> Share

    October 2021
  37. GILL PK, Hegele RA
    Familial combined hyperlipidemia is a polygenic trait.
    Curr Opin Lipidol. 2021 Oct 22. pii: 00041433-900000000-99252.
    >> Share

  38. MCINTOSH CS, Watts GF, Wilton SD, Aung-Htut MT, et al
    Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations.
    Curr Opin Lipidol. 2021 Oct 15. pii: 00041433-900000000-99253.
    >> Share

  39. GRAHAM DF, Raal FJ
    Management of familial hypercholesterolemia in pregnancy.
    Curr Opin Lipidol. 2021 Oct 6. pii: 00041433-900000000-99256.
    >> Share

    September 2021
  40. THOMPSON GR
    Use of apheresis in the age of new therapies for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2021 Sep 22. pii: 00041433-900000000-99259.
    >> Share

    August 2021
  41. IQBAL Z, Bashir B, Ferdousi M, Kalteniece A, et al
    Lipids and peripheral neuropathy.
    Curr Opin Lipidol. 2021;32:249-257.
    >> Share

  42. DRON JS, Hegele RA
    Editorial: Discussing polygenic risk with lipid clinic patients.
    Curr Opin Lipidol. 2021;32:273-275.
    >> Share

    June 2021
  43. BERBERICH AJ, Hegele RA
    Lipid effects of glucagon-like peptide 1 receptor analogs.
    Curr Opin Lipidol. 2021;32:191-199.
    >> Share

    April 2021
  44. MOHAMED F, Botha TC, Raal FJ
    Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Curr Opin Lipidol. 2021 Apr 20. pii: 00041433-900000000-99277.
    >> Share

  45. PULIPATI VP, Davidson MH
    The clinical black, white, and gray lessons.
    Curr Opin Lipidol. 2021;32:151-156.
    >> Share

  46. WAND H, Knowles JW, Clarke SL
    The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case.
    Curr Opin Lipidol. 2021;32:89-95.
    >> Share

  47. BROWN EE
    The genetic counselor's role in management of patients with dyslipidemia.
    Curr Opin Lipidol. 2021;32:83-88.
    >> Share

  48. TRINDER M, Brunham LR
    Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance.
    Curr Opin Lipidol. 2021;32:103-111.
    >> Share

  49. FONG V, Patel SB
    Recent advances in ABCG5 and ABCG8 variants.
    Curr Opin Lipidol. 2021;32:117-122.
    >> Share

    February 2021
  50. CHORA JR, Bourbon M
    Pharmacogenomics of statins and familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Feb 10. pii: 00041433-900000000-99283.
    >> Share

    October 2020
  51. YEANG C, Willeit P, Tsimikas S
    The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000713.
    >> Share

  52. IBRAHIM S, Reeskamp LF, Stroes ESG, Watts GF, et al
    Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000714.
    >> Share

    September 2020
  53. WOLSKA A, Yang ZH, Remaley AT
    Hypertriglyceridemia: new approaches in management and treatment.
    Curr Opin Lipidol. 2020 Sep 29. doi: 10.1097/MOL.0000000000000710.
    >> Share

    June 2020
  54. SORAN H, Cooper JA, Durrington PN, Capps N, et al
    Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register.
    Curr Opin Lipidol. 2020 Jun 28. doi: 10.1097/MOL.0000000000000692.
    >> Share

  55. BELANGER AM, Akioyamen L, Alothman L, Genest J, et al
    Evidence for improved survival with treatment of homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Jun 8. doi: 10.1097/MOL.0000000000000686.
    >> Share

    April 2020
  56. BRANDTS J, Dharmayat KI, Ray KK, Vallejo-Vaz AJ, et al
    Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000675.
    >> Share

  57. BAJAJ A, Cuchel M
    Homozygous familial hypercholesterolemia: what treatments are on the horizon?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000677.
    >> Share

    January 2020
  58. D'ERASMO L, Di Costanzo A, Arca M
    Autosomal recessive hypercholesterolemia: update for 2020.
    Curr Opin Lipidol. 2020 Jan 31. doi: 10.1097/MOL.0000000000000664.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016